In a recent report by Labiotech.eu, the renowned online media focusing on the European biotechnology industry, Leman Biotech has been recognized as one of the 13 exceptional biotech companies in Switzerland's "Health Valley." The report highlights Leman Biologics' groundbreaking work in developing the metabolic regulator protein IL-10-Fc, which enhances the effectiveness of existing immunotherapy treatments like CAR-T by boosting T-cell metabolism.
Preclinical studies have shown remarkable results, with IL-10-Fc significantly increasing the cure rates of second-generation conventional CAR-T therapy in mouse models of rectal cancer and melanoma. Additionally, when combined with PD-1 antibody therapy in a rectal cancer mouse model, IL-10-Fc demonstrated substantial improvement. Leman Biotech is currently advancing its large molecule pipeline in the preclinical CMC stage, while their metabolism-enhanced CAR-T has entered the IIT clinical study stage.
With successful angel round financing completed, Leman Biotech is now pursuing angel+ round financing to expedite IND filing for biomacromolecular drugs and novel cellular therapies. Leman Biotech remains committed to optimizing its core technologies and product pipeline, striving towards the ultimate goal of curing solid tumors and contributing to a healthier future.
Established in 2014, Labiotech.eu has become one of Europe's most prominent biotechnology websites, providing comprehensive coverage of the latest developments in the life science industry and fostering an ecosystem for open discussions and knowledge exchange in biotechnology.
For more information, please refer to:
https://www.labiotech.eu/best-biotech/13-biotech-companies-western-switzerland/
